Related Experiment Video
Updated: Feb 18, 2026

Generation of Human Neurons and Oligodendrocytes from Pluripotent Stem Cells for Modeling Neuron-Oligodendrocyte Interactions
Published on: November 9, 2020
Neural cells generated from human induced pluripotent stem cells as a model of CNS involvement in
Jitka Rybová1, Jana Ledvinová1, Jakub Sikora1,2
1Rare Diseases Research Unit, Department of Pediatrics and Adolescent Medicine, Charles University, Ke Karlovu 2, Prague, 12808, Czech Republic.
Abstract:
Mucopolysaccharidosis type II (MPSII) is a rare X-linked lysosomal storage disorder caused by mutations in the iduronate-2-sulfatase (IDS) gene (IDS, Xq28). MPSII is characterized by skeletal deformities, hearing loss, airway obstruction, hepatosplenomegaly, cardiac valvular disease, and progressive neurological impairment. At the cellular level, IDS deficiency leads to lysosomal storage of glycosaminoglycans (GAGs), dominated by accumulation of dermatan and heparan sulfates. Human induced pluripotent stem cells (iPSC) represent an alternative system that complements the available MPSII murine model. Herein we report on the reprogramming of peripheral white blood cells from male and female MPSII patients into iPSC using a non-integrating protocol based on the Sendai virus vector system. We differentiated the iPSC lines into IDS deficient and GAG accumulating β-Tubulin III+ neurons, GFAP+ astrocytes, and CNPase+ oligodendrocytes. The lysosomal system in these cells displayed structural abnormalities reminiscent of those previously found in patient tissues and murine IDS deficient neuronal stem cells. Furthermore, quantitative determination of GAGs revealed a moderate increase in GAG levels in IDS deficient neurons and glia. We also tested the effects of recombinant IDS and found that the exogenous enzyme was internalized from the culture media and partially decreased the intracellular GAG levels in iPSC-derived neural cells; however, it failed to completely prevent accumulation of GAGs. In summary, we demonstrate that this human iPSC based model expresses the cellular and biochemical features of MPSII, and thus represents a useful experimental tool for further pathogenesis studies as well as therapy development and testing.
Insights
Mucopolysaccharidosis type II (MPSII) is a rare genetic disorder. Researchers created a human stem cell model to study MPSII, showing promise for understanding the disease and testing therapies.
Area of Science:
- Genetics and rare diseases
- Cell biology and regenerative medicine
- Biochemistry and metabolic disorders
Background:
- Mucopolysaccharidosis type II (MPSII) is an X-linked lysosomal storage disorder caused by iduronate-2-sulfatase (IDS) gene mutations.
- Cellular hallmark of MPSII is the accumulation of glycosaminoglycans (GAGs) due to IDS deficiency.
- Existing MPSII models, primarily murine, have limitations; human induced pluripotent stem cells (iPSCs) offer a complementary system.
Purpose of the Study:
- To establish and characterize a human iPSC-based model for MPSII.
- To investigate the cellular and biochemical features of MPSII in iPSC-derived neural cells.
- To evaluate the potential of recombinant IDS enzyme therapy in this human model.
Main Methods:
- Reprogramming of peripheral white blood cells from MPSII patients into iPSCs using a non-integrating Sendai virus vector system.
- Differentiation of iPSCs into neurons, astrocytes, and oligodendrocytes.
- Analysis of lysosomal structure, GAG accumulation, and response to recombinant IDS treatment.
Main Results:
- Successfully generated MPSII patient-derived iPSC lines.
- iPSC-derived neural cells exhibited lysosomal abnormalities and GAG accumulation characteristic of MPSII.
- Recombinant IDS showed partial GAG reduction but did not fully resolve accumulation in vitro.
- The human iPSC model recapitulates key MPSII cellular and biochemical phenotypes.
Conclusions:
- The developed human iPSC model accurately reflects MPSII cellular and biochemical features.
- This model serves as a valuable tool for studying MPSII pathogenesis.
- The model is suitable for preclinical testing of novel therapeutic strategies for MPSII.
Related Concept Videos
EPS and iPS Cells in Disease Research
Induced Pluripotent Stem Cells
Somatic...
Induced Pluripotent Stem Cells
iPS Cell Differentiation

